PT  - JOURNAL ARTICLE
AU  - Kurashige, Takushi
AU  - Noguchi, Yuji
AU  - Saika, Takashi
AU  - Ono, Toshiro
AU  - Nagata, Yasuhiro
AU  - Jungbluth, Achim
AU  - Ritter, Gerd
AU  - Chen, Yao-Tseng
AU  - Stockert, Elisabeth
AU  - Tsushima, Tomoyasu
AU  - Kumon, Hiromi
AU  - Old, Lloyd J.
AU  - Nakayama, Eiichi
TI  - NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma
DP  - 2001 Jun 15
TA  - Cancer Research
PG  - 4671--4674
VI  - 61
IP  - 12
4099  - http://cancerres.aacrjournals.org/content/61/12/4671.short
4100  - http://cancerres.aacrjournals.org/content/61/12/4671.full
SO  - Cancer Res2001 Jun 15; 61
AB  - NY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY-ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5%) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ. ©2001 American Association for Cancer Research.